1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Axial Spondyloarthritis (axSpA) - Epidemiology Insight - 2030

Axial Spondyloarthritis (axSpA) - Epidemiology Insight - 2030

  • April 2021
  • 100 pages
  • ID: 6064462
  • Format: PDF
  • Delve Insight


Table of Contents

‘Axial Spondyloarthritis (AxSpA)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the axSpA, historical and forecasted epidemiology as well as the axSpA trends in the United States.

Axial Spondyloarthritis (axSpA) Disease Understanding
Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition that consists of two subsets, which clinically have been defined as ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Nr-axSpA is characterized by the absence of definitive x-ray evidence of structural damage to the sacroiliac (SI) joint by plain x-ray. Since the SI joint x-ray interpretation is subjective, the distinction between nr-axSpA and AS is not absolute. Sacroiliitis (inflammation of the SI joint) and inflammation of the spine are predominant features of axSpA; hence patients typically present with inflammatory back pain. Other manifestations, such as enthesitis, dactylitis, peripheral arthritis, anterior uveitis, psoriasis, and inflammatory bowel disease, are common. Over time many patients with nr-axSpA develop the structural damage of sacroiliac joints, ultimately progressing to AS; however, some nr-axSpA patients will never advance to this stage. The clinical manifestations for axSpA and nr-axSpA are similar to the patients’ disease burden experience.
Patients with axSpA commonly complain of back pain that starts before 45 years of age. Back pain’s characteristic features include chronicity (>3 months), insidious onset, improvement with exercise, an occurrence at night with improvement upon waking, and no rest. Inflammatory back pain (IBP) criteria are essential in screening for axSpA. Among at-risk patients, the sensitivity of IBP (approximately 70–95%) for axSpA is relatively high (back pain >3 months with onset age).
Continued in the report…..
Axial Spondyloarthritis (axSpA) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Axial Spondyloarthritis, Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis scenario in the United States, from 2018 to 2030.
Axial Spondyloarthritis (axSpA) Detailed Epidemiology Segmentation
• The total prevalent population of Axial Spondyloarthritis (axSpA) in the US was estimated to be 3,122,331 in 2020 which is anticipated to rise till 2030. Out of the total prevalent population, 1,336,050 cases were diagnosed in 2020.
• In the epidemiology model, different age-groups are included, i.e., 18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, and 70+ years. It is estimated that the most prevalent age-group for axSpA in the United States was 40–49 years in 2020.
• The total prevalent population of nr-axSpA and AS in the US was estimated to be 1,821,360 and 1,300,971 in 2020, respectively.
• In 2020, out of the total diagnosed cases of nr-axSpA, 670,252 cases had HLA-B27 gene mutation, and 109,111 cases involved other genes (ERAP 1, IL-12, IL-17, and IL-23). Additionally, in cases of AS, out of the total diagnosed cases in 2020, 501,019 cases involved HLA-B27 gene, and 55,669 cases had other genes involvement.
• The prevalent population of AS showed a male predominance, whereas nr-axSpA showed a female predominance. Out of the total diagnosed population of nr-axSpA 779,363 cases in the US, 335,126 and 444,237 cases were contributed by males and females, respectively, in 2020.

Scope of the Report
• The report covers the descriptive overview of AXSPA, explaining its causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the historical and forecasted patient pool covering the United States.
• The report assesses the disease risk and burden and highlights the unmet needs of AXSPA.
• The report helps to recognize the growth opportunities in the United States with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for the United States by Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis.

“The diagnosis of axial spondyloarthritis (axSpA) can be tough to spot as so many people have back pain—its main symptom. Additionally, there are no specific lab tests to identify the condition. All these factors play a major role in the low diagnosis of axSpA. Gender difference in both the types of axSpA has shown different trend. In case of nr-axSpA, female dominance is observed, whereas in AS, male dominance is there.”

Report Highlights
• 10-Year Forecast of axSpA
• United States Coverage
• Total Prevalent Cases of Axial Spondyloarthritis
• Total Diagnosed Prevalent Cases of Axial Spondyloarthritis
• Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
• Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
• Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis

Key Questions Answered
• What are the disease risk, and burden of axSpA?
• What is the historical axSpA patient pool in the United States?
• What would be the forecasted patient pool of axSpA at the United States level?
• What will be the growth opportunities across the United States with respect to the patient population pertaining to axSpA?
• Out of the above-mentioned countries, which country would have the highest prevalent population of axSpA during the forecast period (2021–2030)?
• At what CAGR the population is expected to grow across the United States during the forecast period (2021–2030)?

Reasons to buy
The AXSPA report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the United States axSpA epidemiology forecast.
• The axSpA epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The axSpA epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
Study Period: 2018–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030

  • $ 3995
  • May 2021
  • 42 pages

Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030 Summary Systemic sclerosis (SSc) is an autoimmune disorder of small arteries, microvessels, and connective tissue.SSc is characterized ...

  • United States
  • Italy
  • Musculoskeletal Disorder
  • Epidemiology
  • Industry analysis
  • Prescription Drug Sales
  • Health Provider Density


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on